“Around 700,000 people around the world die annually due to drug-resistant infections. If no action is taken, it has been estimated that drug-resistant infections will kill 10 million people a year by 2050”
Dame Sally Davies, UK Chief Medical Officer (AMR review)
Hour delay in current testing
Increase in daily antibiotic use
Hospitalised with resistant infections (UK)
“Fighting Antimicrobial Resistance with Rapid POC diagnostics”
FluoretiQ have developed NANOPLEX™- a rapid diagnostic platform that identifies and enumerates bacterial pathogens in less than 15 minutes; ensuring that patients receive the most effective antibiotic treatment from the start.
NANOPLEX™ uses a library of glycan-based probes that have been engineered to exploit the adhesion phase of infection. Our chemistry is tuned to be able to assign identity within a sample and determine whether a clinically significant concentration is present.
Our probe library can currently identify 95% of commonly identified uropathogens including Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Pseudomonas aeruginosa and Staphylococcus saprophyticus.
A message from our CEO, Neciah Dorh
“Even with new drugs under development, the only way to safeguard the future is to develop the right diagnostic tools to allow us to quickly identify bacteria at the point of consultation”
NANOPLEX can offer clinical information to the physician at the point of care, reducing the need for empirical antibiotic use”.
Saving Time, Saving Money, Saving Lives.